Elicera Therapeutics AB (publ) (ELIC.ST)
SEK 4.44
(4.72%)
SEK 4.44
(4.72%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 30.17 Million SEK | -34.84% |
| 2022 | 46.3 Million SEK | -15.4% |
| 2021 | 54.73 Million SEK | 334.78% |
| 2020 | 12.58 Million SEK | 1936.85% |
| 2019 | 618.1 Thousand SEK | -23.61% |
| 2018 | 809.16 Thousand SEK | -0.43% |
| 2017 | 812.68 Thousand SEK | -13.38% |
| 2016 | 938.24 Thousand SEK | -20.84% |
| 2015 | 1.18 Million SEK | 20.02% |
| 2014 | 987.5 Thousand SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 33.86 Million SEK | -18.24% |
| 2024 Q1 | 41.41 Million SEK | 37.25% |
| 2023 FY | 30.17 Million SEK | -34.84% |
| 2023 Q1 | 43.84 Million SEK | -5.32% |
| 2023 Q4 | 30.17 Million SEK | 7.18% |
| 2023 Q3 | 28.15 Million SEK | -31.39% |
| 2023 Q2 | 41.03 Million SEK | -6.41% |
| 2022 Q2 | 45.34 Million SEK | -8.0% |
| 2022 Q3 | 41.25 Million SEK | -9.02% |
| 2022 Q4 | 46.3 Million SEK | 12.24% |
| 2022 FY | 46.3 Million SEK | -15.4% |
| 2022 Q1 | 49.28 Million SEK | -9.96% |
| 2021 Q1 | 9.23 Million SEK | -26.66% |
| 2021 FY | 54.73 Million SEK | 334.78% |
| 2021 Q4 | 54.73 Million SEK | -2.14% |
| 2021 Q3 | 55.93 Million SEK | -17.46% |
| 2021 Q2 | 67.76 Million SEK | 634.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q4 | 12.58 Million SEK | 0.0% |
| 2020 FY | 12.58 Million SEK | 1936.85% |
| 2019 FY | 618.1 Thousand SEK | -23.61% |
| 2018 FY | 809.16 Thousand SEK | -0.43% |
| 2017 FY | 812.68 Thousand SEK | -13.38% |
| 2016 FY | 938.24 Thousand SEK | -20.84% |
| 2015 FY | 1.18 Million SEK | 20.02% |
| 2014 FY | 987.5 Thousand SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Active Biotech AB (publ) | 44 Million SEK | 31.425% |
| Biovica International AB (publ) | 131.4 Million SEK | 77.039% |
| Cantargia AB (publ) | 223.71 Million SEK | 86.513% |
| CombiGene AB (publ) | 120.61 Million SEK | 74.983% |
| Cyxone AB (publ) | 43.65 Million SEK | 30.883% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -5.841% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 61.657% |
| Fluicell AB (publ) | 9.34 Million SEK | -223.052% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 91.412% |
| Mendus AB (publ) | 755.95 Million SEK | 96.009% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 78.539% |
| I-Tech AB | 152.44 Million SEK | 80.207% |
| Intervacc AB (publ) | 259.61 Million SEK | 88.378% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 10.205% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 89.175% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -50.557% |
| OncoZenge AB (publ) | 20.34 Million SEK | -48.343% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 51.628% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 95.383% |
| Lipum AB (publ) | 12.11 Million SEK | -149.158% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 74.527% |
| Ziccum AB (publ) | 14.97 Million SEK | -101.53% |
| BioArctic AB (publ) | 1.18 Billion SEK | 97.456% |
| Genovis AB (publ.) | 288.85 Million SEK | 89.554% |
| Camurus AB (publ) | 1.9 Billion SEK | 98.418% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 82.965% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 51.453% |
| Aptahem AB (publ) | 63.02 Million SEK | 52.125% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 93.92% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 96.057% |
| Kancera AB (publ) | 65.64 Million SEK | 54.035% |
| Saniona AB (publ) | 64.14 Million SEK | 52.96% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 43.054% |
| AcouSort AB (publ) | 34.51 Million SEK | 12.575% |
| Xintela AB (publ) | 18.39 Million SEK | -64.028% |
| Abliva AB (publ) | 87.49 Million SEK | 65.516% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 97.602% |
| Amniotics AB (publ) | 26.08 Million SEK | -15.668% |
| 2cureX AB (publ) | 16.62 Million SEK | -81.492% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -396.512% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 98.412% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 97.036% |
| Biosergen AB | 7.2 Million SEK | -319.012% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 28.089% |
| Corline Biomedical AB | 100.1 Million SEK | 69.859% |
| NextCell Pharma AB | 81.28 Million SEK | 62.881% |
| Nanologica AB (publ) | 77.42 Million SEK | 61.031% |
| LIDDS AB (publ) | 17.65 Million SEK | -70.904% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 96.031% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 97.845% |
| SynAct Pharma AB | 228.01 Million SEK | 86.767% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -12.742% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -39.028% |
| Alzinova AB (publ) | 123.18 Million SEK | 75.507% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 65.347% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 87.342% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -256.866% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 64.597% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -102.926% |
| Simris Alg AB (publ) | 174.55 Million SEK | 82.714% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 86.098% |